Select the drug indication to add to your list


Miscellaneous ocular agents
Only 4 drugs may be compared at once

Generic Name and Formulations:

Ranibizumab 6mg/mL, 10mg/mL; soln for oph intravitreal inj; preservative-free.


Genentech, Inc.

Select therapeutic use:

Indications for LUCENTIS:

Neovascular (wet) age-related macular degeneration (AMD). Macular edema following retinal vein occlusion (RVO). Diabetic macular edema (DME). Diabetic retinopathy (DR). Myopic choroidal neovascularization (mCNV).


Give by intravitreal inj. AMD: 0.5mg once a month (approx. 28 days); or 3 monthly doses followed by less frequent dosing (less effective); or 0.5mg every 3 months after 4 monthly doses (less effective). Monitor regularly. RVO: 0.5mg once a month (approx. 28 days). DME, DR: 0.3mg once a month (approx. 28 days). mCNV: 0.5mg once a month (approx. 28 days) for up to 3 months; may retreat if needed.


Not established.


Ocular or periocular infections.


Monitor intraocular pressure prior to and 30 mins after inj. Monitor for perfusion of optic nerve and for infection following the inj (endophthalmitis and retinal detachments possible). Risk of embryo-fetal toxicity. Pregnancy. Nursing mothers.

Pharmacological Class:

Vascular endothelial growth factor (VEGF) inhibitor.

Adverse Reactions:

Conjunctival hemorrhage, eye pain, vitreous floaters, increased intraocular pressure, intraocular inflammation; rare: arterial thromboembolic events, fatal events.

Generic Availability:


How Supplied:

Single-use prefilled syringe (10mg/mL)—1; Single-use vial (6mg/mL, 10mg/mL)—1

LUCENTIS 0.05ml of 0.5mg vials (Qty:1)

appx. price $2047.00